The potential of autologous patient-derived circulating extracellular vesicles to improve drug delivery in rheumatoid arthritis
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxae101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Ori Moskovitch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Extracellular Vesicles, Drug Delivery Systems, Arthritis, Experimental. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Yaron and Gila Shemie Foundation.
Abstract (Originalsprache)
Recognizing the need for innovative therapeutic approaches in the management of autoimmune diseases, our current investigation explores the potential of autologous extracellular vesicles (EVs), derived from the blood of rheumatoid arthritis patients, to serve as therapeutic vectors to improve drug delivery. We found that circulating EVs derived from arthritic mice (collagen-induced arthritis model) express the joint/synovia homing receptor, αVβ3 integrin. Importantly, both autologous labeled EVs, derived from the blood of arthritic mice (collagen antibody-induced arthritis model) and healthy mice-derived EVs, exhibit targeted migration toward inflamed synovia without infiltrating healthy joints, as demonstrated by an in vivo imaging system. Furthermore, EVs derived from plasma of rheumatoid arthritis patients show an overexpression of αV integrin and are effectively taken up by lipopolysaccharides/tumor necrosis factor alpha (TNFα)-induced activated human synovial cell line in vitro, although interestingly the uptake of healthy EVs was found to be significantly increased. Notably, arthritic mice-derived circulating EVs, strongly express murine glucose transporter 1, which in turn can facilitate their binding to glucose-coated gold nanoparticles (previously shown to be conjugated with drugs for improved drug delivery). The significance of our results, lies in the identification of autologous tissue homing EVs as promising vectors, offering a novel avenue to enhance targeted delivery of anti-inflammatory/rheumatic drugs in rheumatoid arthritis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.
- The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Bar-Ilan Institute for Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, Ramat Gan, Israel.
- Faculty of Medicine, Neufeld Cardiovascular Research Institutes, Tel Aviv University, Tel-Aviv, Israel.
- Tamman Cardiovascular Research Institutes, Sheba Medical Center, Tel-Hashomer, Israel.
- The Department of Molecular Biology, Ariel University, Ariel, Israel.
ORCID-Profile: Abdulla Watad, Howard Amital, Gilad Halpert
Förderung
- Yaron and Gila Shemie Foundation
Zitieren
APA
Moskovitch, O., Anaki, A., Caller, T., Gilburd, B., Segal, O., Gendelman, O., Watad, A., Mehrian-Shai, R., Mintz, Y., Segev, S., Shoenfeld, Y., Popovtzer, R., Amital, H., & Halpert, G. (2025). The potential of autologous patient-derived circulating extracellular vesicles to improve drug delivery in rheumatoid arthritis. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae101
Vancouver
Moskovitch O, Anaki A, Caller T, Gilburd B, Segal O, Gendelman O, et al. The potential of autologous patient-derived circulating extracellular vesicles to improve drug delivery in rheumatoid arthritis. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae101
BibTeX
@article{Moskovitch2025,
author = {Moskovitch, Ori and Anaki, Adi and Caller, Tal and Gilburd, Boris and Segal, Ori and Gendelman, Omer and Watad, Abdulla and Mehrian-Shai, Ruty and Mintz, Yael and Segev, Shlomo and Shoenfeld, Yehuda and Popovtzer, Rachela and Amital, Howard and Halpert, Gilad},
title = {The potential of autologous patient-derived circulating extracellular vesicles to improve drug delivery in rheumatoid arthritis},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxae101}
}
EUVIMED